

Overall survival results inside



A path forward for patients with HRRm mCRPC

USE

TALZENNA is a prescription medicine used in combination with a medicine called enzalutamide, to treat adults with prostate cancer

- with certain abnormal inherited or acquired genes called homologous recombination repair (HRR genes) **and**
- which no longer responds to hormone therapy or surgical treatment to lower testosterone and has spread to other parts of the body (metastatic).

Your healthcare provider will perform a test to make sure that TALZENNA is right for you.

It is not known if TALZENNA is safe and effective in children.

Not a real patient.

HRRm = homologous recombination repair gene-mutated; mCRPC = metastatic castration-resistant prostate cancer.

IMPORTANT SAFETY INFORMATION

TALZENNA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).

Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with TALZENNA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with TALZENNA.

See page 2 for more information about this side effect.

Please see additional Important Safety Information throughout. Click for the full TALZENNA [Patient Information](#) or visit [TALZENNAXTANDI.com](https://www.talzenna.com). Please talk to your doctor or see XTANDI Patient Information for Important Safety Information about XTANDI.

Starting TALZENNA + XTANDI



TALZENNA® (talazoparib) is a prescription medicine used in combination with a medicine called XTANDI® (enzalutamide) to treat adults with **metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations** (HRR gene-mutated mCRPC).


HRR gene-mutated mCRPC is a type of prostate cancer with certain abnormal genes (HRR gene mutations) that can be inherited or acquired. The cancer has spread to other parts of the body (metastatic) and no longer responds to hormone therapy or surgical treatment to lower testosterone (castration-resistant).


HRR gene mutations explained

HRR is a process in which a group of genes work together to repair damage to your DNA. If you have mutations in HRR genes, not all DNA repair proteins may work properly. This may increase your chances of developing certain types of cancers, including prostate cancer.

Once-daily oral treatment

TALZENNA is a pill—not chemotherapy or an injection. It’s taken:


Once a day


With or without food

There are 2 types of HRR gene mutations:

Inherited
Passed on from parent to child

Acquired
Can occur randomly and throughout your lifetime

~ 1 in 4 men with mCRPC have an HRR gene mutation*

*This is an estimate because the studies and data used to determine the occurrence of HRR gene mutations in men with advanced prostate cancer varied in their design and patient characteristics, such as previous or current drug treatment, coexisting conditions, or disease levels.



Not real patients.



Why HRR status matters

For starters, knowing your HRR status can inform your treatment options, including whether you might be eligible for TALZENNA + XTANDI. But it can also:

- Help you and your doctor decide how to manage your prostate cancer
- Help you find out if your family is at an increased risk of developing certain types of cancers since these mutations may be inherited



How HRR gene mutations are identified

A doctor may run a genetic and/or biomarker test using a blood or tissue sample to check for any inherited or acquired gene mutations.

Ask your doctor about your HRR mutation status

They may have already tested for HRR mutations and can review the results with you. If this testing hasn't been done yet, your doctor can help coordinate the appropriate genetic test.

IMPORTANT SAFETY INFORMATION

TALZENNA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). (Continued)

Symptoms of low blood cell counts are common during treatment with TALZENNA, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with TALZENNA:

- weakness
- fever
- blood in urine or stool
- feeling very tired
- weight loss
- frequent infections
- shortness of breath
- bruising or bleeding more easily

Your healthcare provider will do blood tests to check your blood cell counts:

- every month during treatment with TALZENNA.
- weekly if you have low blood cell counts that last a long time.

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TALZENNA if you get certain side effects.

Before taking TALZENNA, tell your healthcare provider about all of your medical conditions, including if you:

- have kidney problems
- are pregnant or plan to become pregnant. TALZENNA can harm your unborn baby, and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with TALZENNA.
 - Males with female partners who are pregnant or are able to become pregnant should use effective birth control during treatment with TALZENNA and for 4 months after the last dose of TALZENNA.
- are breastfeeding or plan to breastfeed. It is not known if TALZENNA passes into your breast milk.

How treatment may help patients with HRRm mCRPC

In a study of patients with HRRm mCRPC, **TALZENNA + XTANDI** reduced the risk of progression and helped patients live longer



The study

TALZENNA® (talazoparib) + XTANDI® (enzalutamide) was studied in a clinical trial in adults with **HRR gene-mutated mCRPC**.

The main goal of the study was to measure progression-free survival, which means how long patients lived without their cancer getting worse or until they died for any reason. Another goal was overall survival, which is the time from diagnosis or the start of treatment until death from any cause.


In the study, 200 patients were given TALZENNA + XTANDI, and 199 patients were given placebo + XTANDI. All patients either had surgery to lower testosterone or continued to take hormone therapy.

The results


Reduced risk of progression

The risk of cancer progression was **reduced by 55% with TALZENNA + XTANDI** vs those taking placebo + XTANDI.

Cancer progression was seen in 66 of the 200 patients taking TALZENNA + XTANDI vs 104 of the 199 patients taking placebo + XTANDI.



Median time until progression




The median length of time until cancer progression was not reached for TALZENNA + XTANDI.* In this clinical trial, patients taking TALZENNA + XTANDI had a 97.5% chance that the median time until cancer progression was at least 21.9 months.

The median length of time until cancer progression was 13.8 months for patients who took placebo + XTANDI.

*“Median not reached” means that more than half of patients were alive without their cancer progressing at the time of analysis.

TALZENNA + XTANDI helped patients live longer vs placebo + XTANDI



- Patients lived for a **median of 3.8 years** (45.1 months) with TALZENNA + XTANDI vs **2.6 years** (31.1 months) with placebo + XTANDI. At the time of this analysis, 93 out of the 200 patients taking TALZENNA + XTANDI had died for any reason vs 126 out of the 199 patients taking placebo + XTANDI

What does “median” mean?

- A median is the middle number in a group of numbers ordered from lowest to highest
- Median time until cancer progression is the length of time until half of the patients receiving treatment had their cancer progress (get worse) or until they die for any reason
- Median survival is the length of time after diagnosis that half of the patients are still alive

Results may vary. Ask your doctor if TALZENNA + XTANDI is right for you.

IMPORTANT SAFETY INFORMATION

The most common side effects of TALZENNA when taken in combination with enzalutamide include:

- | | | |
|-------------------------------------|------------------------------------|------------------------------------|
| • decreased red blood cell counts | • decreased appetite | • increased bilirubin in the blood |
| • decreased white blood cell counts | • decreased sodium in the blood | • decreased potassium in the blood |
| • tiredness or weakness | • decreased phosphate in the blood | • changes in your sense of taste |
| • decreased platelet counts | • bone injuries | |
| • decreased calcium in the blood | • decreased magnesium in the blood | |
| • nausea | • dizziness | |




How TALZENNA® (talazoparib) works

The DNA in the nucleus of your cells tells your body how to form and function. DNA is arranged in groupings called genes, which make proteins that drive this process. Importantly, DNA regulates the ability of cells to duplicate to keep the process going. But DNA can become damaged.




When there's damaged DNA, called breaks in the DNA strands, proteins such as PARP,* which exist in your cells, help repair the breaks to keep the cells functioning. This occurs for both normal and cancerous cells.

*PARP = poly (ADP-ribose) polymerase.



HRR provides another mechanism for DNA repair. In cells, there may be damage to HRR genes due to mutations. Mutated HRR genes prevent proteins associated with the pathway from being effective in DNA repair.



TALZENNA is for men whose prostate cancer has an HRR gene mutation. TALZENNA works by inhibiting the repair protein, PARP, from activating the cell's repair pathway. This, in combination with the dysfunction of the mutated HRR gene, makes it harder for cancer cells to survive. TALZENNA can also affect normal cells, which can lead to side effects.



This is how TALZENNA was shown to work in laboratory studies. Clinical significance is unknown.


How XTANDI® (enzalutamide) works

XTANDI is an androgen receptor inhibitor.



Androgens are a group of hormones that include testosterone. Androgen receptor inhibitors decrease how often androgens like testosterone connect with an androgen receptor, and thereby may slow the growth of prostate cancer tumors and cells. Let's take a look inside the cell.

When androgen connects with an androgen receptor, it may cause tumor cells to grow.



XTANDI helps decrease how often androgen can connect with an androgen receptor. As a result, XTANDI can slow cancer cell growth and the cancer cells may die.

This is how XTANDI was shown to work in laboratory studies. Clinical significance is unknown.

Please talk to your doctor or see XTANDI Patient Information for Important Safety Information about XTANDI.

IMPORTANT SAFETY INFORMATION

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking TALZENNA with certain other medicines can affect how TALZENNA works and may cause side effects.

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.



IMPORTANT SAFETY INFORMATION and USE

TALZENNA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with TALZENNA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with TALZENNA.

Symptoms of low blood cell counts are common during treatment with TALZENNA, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with TALZENNA:

- weakness
- weight loss
- fever
- frequent infections
- blood in urine or stool
- shortness of breath
- feeling very tired
- bruising or bleeding more easily

Your healthcare provider will do blood tests to check your blood cell counts:

- every month during treatment with TALZENNA.
- weekly if you have low blood cell counts that last a long time.

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TALZENNA if you get certain side effects.

Before taking TALZENNA, tell your healthcare provider about all of your medical conditions, including if you:

- have kidney problems
- are pregnant or plan to become pregnant. TALZENNA can harm your unborn baby, and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with TALZENNA.
 - Males with female partners who are pregnant or are able to become pregnant should use effective birth control during treatment with TALZENNA and for 4 months after the last dose of TALZENNA.
- are breastfeeding or plan to breastfeed. It is not known if TALZENNA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking TALZENNA with certain other medicines can affect how TALZENNA works and may cause side effects.

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How to take TALZENNA

- Take TALZENNA exactly as your healthcare provider tells you.
- Do not change your dose or stop taking TALZENNA without first talking with your healthcare provider.
- You should start or continue a gonadotropin-releasing hormone (GnRH) analog therapy during your treatment with TALZENNA and enzalutamide unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).
- If you vomit or miss a dose of TALZENNA, take your next dose at your regular time. Do not take an extra dose to make up for a missed dose.

The most common side effects of TALZENNA when taken in combination with enzalutamide include:

- decreased red blood cell counts
- decreased white blood cell counts
- tiredness or weakness
- decreased platelet counts
- decreased calcium in the blood
- nausea
- decreased appetite
- decreased sodium in the blood
- decreased phosphate in the blood
- bone injuries
- decreased magnesium in the blood
- dizziness
- increased bilirubin in the blood
- decreased potassium in the blood
- changes in your sense of taste

TALZENNA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of TALZENNA. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

What is TALZENNA?

TALZENNA is a prescription medicine used in combination with a medicine called enzalutamide, to treat adults with prostate cancer

- with certain abnormal inherited or acquired genes called homologous recombination repair (HRR genes) **and**
- which no longer responds to hormone therapy or surgical treatment to lower testosterone and has spread to other parts of the body (metastatic).

Your healthcare provider will perform a test to make sure that TALZENNA is right for you.

It is not known if TALZENNA is safe and effective in children.

Learn more about certain side effects

Before you start taking TALZENNA® (talazoparib) + XTANDI® (enzalutamide), it's important to know what to expect during treatment. Stay informed and work with your doctor to identify and help manage any side effects that you may experience.

Monitoring blood cell counts

Some side effects like decreased red/white blood cell counts, decreased calcium in the blood, and decreased platelet counts can only be seen through blood tests, which your doctor will do:

- every month during treatment with TALZENNA
- weekly if you have low blood cell counts that last a long time.

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with TALZENNA if you get certain side effects.

Common side effects

The most common side effects of TALZENNA when taken in combination with XTANDI include:

- decreased red blood cell counts
- decreased white blood cell counts
- tiredness or weakness
- decreased platelet counts
- decreased calcium in the blood
- nausea
- decreased appetite
- decreased sodium in the blood
- decreased phosphate in the blood
- bone injuries
- decreased magnesium in the blood
- dizziness
- increased bilirubin in the blood
- decreased potassium in the blood
- changes in your sense of taste

TALZENNA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of TALZENNA. Call your doctor for medical advice about side effects.

Your doctor may modify your treatment dose or have other suggestions that could be helpful.



Please see additional Important Safety Information throughout. Click for the full TALZENNA Patient Information or visit [TALZENNAXTANDI.com](https://www.talzenna.com). Please talk to your doctor or see XTANDI Patient Information for Important Safety Information about XTANDI.

Tips that may help with certain side effects

Below you'll find some lifestyle changes that may help manage certain side effects. These tips come from organizations that focus on supporting patients and have not been studied with TALZENNA. Check with your doctor to see which may be right for you.

Decreased red blood cell counts

Treatment may cause a decrease in the number of red blood cells, known as anemia. Anemia may make you feel very tired, short of breath, and/or lightheaded.



Tip: Ask your doctor if any dietary changes or supplements could be helpful.

Decreased white blood cell counts

During treatment, you may experience a decrease in white blood cell numbers, which could put you at an increased risk of infection.



Tip: Remember to wash your hands often and minimize your exposure to people who may be sick.

Tiredness or weakness

While on treatment, you may experience fatigue. Anemia could also contribute to the feeling of tiredness or weakness.



Tip: Talk with your doctor about the amount of rest and kinds of activities that are right for you.

Decreased platelet counts

Platelets are cells that help your blood to clot and stop bleeding. Treatment may cause the number of blood-platelet cells to decrease, which could increase your risk of bruising and bleeding.



Tip: Discuss all over-the-counter medicines you're taking with your doctor, especially those that may increase your risk of bleeding.

Decreased calcium in the blood

Treatment may cause decreased levels of calcium in the blood. This may lead to muscle cramps, especially in your back and legs.



Tip: Talk to your doctor about how you might be able to help maintain your calcium levels.

Nausea

During treatment, you may experience nausea or an upset stomach.



Tip: It may be helpful to eat several small meals throughout the day instead of 3 large ones. It may help to slowly sip liquids throughout the day.

Decreased appetite

Treatment may lower your appetite, which could lead to not eating enough nutrients. Nausea may also contribute to loss of appetite.



Tip: Speak with your care team about foods that might be most nourishing for you.

Decreased sodium in the blood

Treatment may cause sodium levels in the blood to be lower than normal. This may cause nausea and vomiting, low energy, and/or headaches.



Tip: There may be dietary suggestions your care team can share that could help increase your sodium levels.

These are not all of the possible side effects of TALZENNA. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Financial assistance resources


Medicare/government insured

For eligible patients with Medicare/Medicare Part D, Medicaid, or other government insurance plans:

- Pfizer Oncology Together™ may be able to help eligible patients search for financial support from alternate funding resources, which may include financial assistance through Extra Help, a Medicare Part D Low-Income Subsidy (LIS) program
- If support from alternate funding resources or Medicare Extra Help is not available, Pfizer Oncology Together will see if patients are eligible for the Pfizer Patient Assistance Program™,* which may be able to provide prescribed Pfizer Oncology medicines for free†

*The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. Free medicines from Pfizer are provided through the Pfizer Patient Assistance Foundation. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

†Pfizer cannot guarantee that enrollment will result in coverage and/or reimbursement.



Not a real patient.

Commercially insured

For patients with eligible commercial, private, employer, and state marketplace health insurance plans:

CO-PAY ASSISTANCE: Eligible, commercially insured patients may pay as little as **\$0 per month for their prescribed Pfizer Oncology treatment.** [Limits, terms, and conditions apply.](#)* Patients may receive up to \$10,000 per product in savings annually.

*Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico.



Uninsured

For eligible patients without any form of healthcare coverage:

- We can check patient eligibility for Medicaid and help them understand how to apply
- Patients who do not qualify for Medicaid may receive free medicine through the Pfizer Patient Assistance Program. Patients must be eligible and reapply as needed

Find support anytime, anywhere



MyTherapy® app

Now customized with TALZENNA content to support you on your treatment journey. It's available on the App Store and Google Play and includes:



Medication reminders

Manage your medications in one place and stay on top of your TALZENNA therapy with **personalized reminders**.



Education

Get informed about your treatment with **articles and content**. Plus, information about side effects.



Support

Find additional support **services and tools** relevant to you and your care.



Progress tracker

Discover ways to **stay on track**—set reminders, log habits, and record progress. You can also download your health report to discuss with your doctor at your next appointment.



THIS IS LIVING WITH CANCER™ PROGRAM

This Is Living With Cancer™ is a program developed by Pfizer Oncology that includes resources designed for all people living with cancer, whether they're currently on a Pfizer treatment or not.



Understanding cancer

Find encouragement, education, and tools to help you navigate your treatment journey.



Health & wellness

Explore articles about healthy living, exercise, and dietary considerations. Plus, find resources on managing depression, anxiety, pain, and more.



Personalized support

Access support and resources that are tailored to your needs, whether you are a patient or caregiver.



LivingWith® app

Stay connected, organized, and informed—all in one place. This free app helps you and your support network better manage daily life with cancer. Available on the App Store and Google Play.




Scan the QR code to download **MyTherapy** and register today

For patients prescribed **TALZENNA® (talazoparib) + XTANDI® (enzalutamide)**



Scan the QR code to visit **ThisIsLivingWithCancer.com**

A free app designed to help manage life with cancer. Download the free **LivingWith®** app to stay organized, ask for support, and manage your care during treatment.



 **TALZENNA**[®] +  **Xtandi**[®]
talazoparib 0.5 mg capsules (enzalutamide)
40 mg tablets | 80 mg tablets



Not real patients.

Get to know more about
TALZENNA

Visit **TALZENNAXTANDI.com**

Please see Important Safety Information throughout. Click for the full TALZENNA [Patient Information](#) or visit TALZENNAXTANDI.com. Please talk to your doctor or see XTANDI Patient Information for Important Safety Information about XTANDI.

TALZENNA[®] is a registered trademark of Pfizer Inc.
XTANDI[®] is a registered trademark of Astellas Pharma Inc.
© 2025 Pfizer Inc. All rights reserved.
PP-TXT-USA-0625 October 2025

